Tales From The Road
This panel brings together biotech and medtech entrepreneurs to tell their stories of raising capital. You’ll hear their firsthand accounts of navigating the fundraising process and raising capital. Topics may include:
• What stumbling blocks had they hit?
• How had they solved the issues, and what had they learned about raising capital?
• How did they go about finding potential investors, and how did they determine which investors they should pursue?
The panel discusses what the early stage fundraising process was like for them and how others can build an outbound marketing campaign to raise money.
• Matthew Davidson, Founding Partner, MGD Ventures
Dr. Davidson is a drug developer with an entrepreneurial mindset. He is the founder and former CEO of Verrica Pharmaceuticals (NASDAQ: VRCA), a drug company focused on medical dermatology. While CEO and Chairman of the Board at Verrica, he led the company from inception into pivotal Phase 3 clinical trials. He invented the core technology and helped raise over $100M in private and public financings. Recently, Dr. Davidson founded MGD Ventures, a Los Angeles based investment and advisory office focused on early-stage, clinically de-risked therapeutic assets. His academic research focused on immuno-oncology, autoimmunity, and cell therapy and was published in high-impact journals including The Lancet, Nature and Nature Medicine. Dr. Davidson graduated from UC Berkeley with a degree in Molecular and Cellular Biology and earned his PhD in Immunology from the Stanford University School of Medicine.
• Gini Deshpande, CEO, NuMedii
A molecular biologist by training, Gini has more than 16 years of experience turning cutting-edge scientific concepts into products that benefit patients. As CEO of NuMedii, Gini structured the company’s critical partnerships with some of the world’s largest pharmaceutical companies including Allergan, Astellas and Aptalis, and raised the initial rounds of financing. Before NuMedii, she helped companies identify optimal markets and whole-product solutions for their groundbreaking technologies, including Affymetrix and iPierian, and led innovation at Children’s Hospital Boston, where she focused on the creation of new devices for the tiniest of patients. Gini has helped commercialize early-stage technologies in research tools, diagnostics and therapeutics and has closed licensing deals worth several million. She received her MS from the University of Pune (India), her PhD in Biological Sciences from Purdue University, and did post-doctoral work at the Massachusetts General Hospital.
• Mark Allen, CEO, Elevian
Dr. Allen is Co-Founder and CEO of Elevian, a preclinical stage company developing therapeutics that target aging. Dr. Allen is a serial entrepreneur and executive, with experience leading organizations from inception to profitable growth to successful exit. Most recently, Dr. Allen was the Founder & CEO of Corticon, sold to Progress (NASD: PRGS), a leading rules engine powering automated decision-making in healthcare, retail, government and financial services. A member of YPO since 2009, Dr. Allen has a BS in Applied Physics from Columbia University and an MD from UCLA.
• Prem Premsrirut, Founder & CEO, Mirimus
Dr. Premsrirut is co-founder of Mirimus, Inc., having established the business and team from the ground up following her scientific training. She is an expert in the development and use of RNAi transgenic mice for fast and flexible validation and toxicity assessment of candidate genes targets in vivo. She was an inventor of technological advancements that lead to the development of a high-throughput platform for rapid and efficient generation of conditional RNAi transgenic mice and pioneered a novel approach for the generation of “speedy” chimeric GEMMs based on rederivation of mouse embryonic stem cells (ESCs) from existing mouse strains with a predisposition to cancer. She has pioneered methods for implementing CRISPR/Cas9 genome editing for the rapid creation of animal models. Dr. Premsrirut was an MD/PhD fellow at SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory. She received her Ph.D. in genetics and cancer biology following her training in the laboratory of Dr. Scott Lowe. Her work focused on the development of transgenic mouse models to study the effects of tumor maintenance on lung cancer using RNA interference. She received her M.D. from Stony Brook School of Medicine and Winthrop University Hospital with an emphasis on trauma surgery. She received a B.A. in Molecular Cell Biology and Biochemistry from UC Berkeley. Dr. Premsrirut is also an alumni of the Goldman Sachs 10KSB entrepreneurship program that provides business education for company growth and acceleration.
• Thomas Lai, CEO, Taipeibio
Professor Lai has been engaged in biomedical material research over 30 years, and is the pioneer researcher in the field of Tissue Regeneration (Harvard Faculty of Medicine, 1990). Series of milestone articles and patents (over 45 countries) were published in major international journals and patent officials. Hold important research and technology development positions including International Journal Reviewer；Policy advisor and grant reviewer at Ministry of Health and Welfare / Ministry of Science and Technology / Ministry of Economic Affairs, Taiwan.